Company Description
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States.
The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
| Country | United States |
| Founded | 1967 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Christopher Giordano |
Contact Details
Address: 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 United States | |
| Phone | 919 855 2100 |
| Website | tenaxthera.com |
Stock Details
| Ticker Symbol | TENX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000034956 |
| CUSIP Number | 88032L209 |
| ISIN Number | US88032L6056 |
| Employer ID | 26-2593535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher T. Giordano | Chief Executive Officer, President and Director |
| Dr. Stuart Rich M.D. | Chief Medical Officer and Director |
| Thomas A. McGauley | Interim Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer |
| Doug Randall | Chief Business Officer |
| Dr. Douglas Hay | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 18, 2025 | SCHEDULE 13G/A | Filing |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 15, 2025 | SCHEDULE 13G/A | Filing |
| Dec 5, 2024 | SCHEDULE 13G | Filing |
| Dec 4, 2024 | 8-K | Current Report |
| Nov 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |